Akcea and Ionis Confirm Positive Trial Results for Hypertriglyceridemia Treatment
Akcea Therapeutics (NASDAQ: AKCA) and Ionis Pharmaceuticals (NASDAQ: IONS) announced on Tuesday the results for a phase 2 trial featuring AKCEA-ANGPTL3- LRx, a drug candidate developed to combat hypertriglyceridemia. Patients with non-alcoholic fatty liver disease, type 2 diabetes, and hypertriglyceridemia (elevated triglyceride levels) showed significant improvements in their blood work.
A total of 105 patients with one of those three conditions were administered AKCEA-ANGPTL3- LRX via subcutaneous injection for six months. The results found there was a significant reduction in the levels of fasting triglycerides in comparison to the placebo, as well as other lipid indicators such as very-low-density lipoprotein (VLDL-C). The drug was well tolerated among patients, with the most common side effect being a mild reaction where the injection was administered. The full details of this study will be presented at a later medical conference, although it wasn't mentioned which one.
Image source: Getty Images.
Source Fool.com
